Search
Chromic chloride
go.drugbank.com/drugs/DB09129ApprovedChromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Damoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigational[L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609]
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
Asoprisnil
go.drugbank.com/drugs/DB06680InvestigationalIt can be used to treat progesterone sensitive myomata.
Alectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalAlectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4...
Hu-rhEGF-rP64k/Mont
go.drugbank.com/drugs/DB15781InvestigationalHu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated
BBM-H803
go.drugbank.com/drugs/DB17700InvestigationalBBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed. … It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.
T-5224
go.drugbank.com/drugs/DB05998ExperimentalT-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.
Ecabet
go.drugbank.com/drugs/DB05265InvestigationalEcabet represents a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia. … Ecabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.